MedQuist Holdings Inc. (NASDAQ: MEDH):
Second Quarter
Highlights
- Total clinical documentation volume
increases 7% compared with the prior-year period to 855 million
lines
- Adjusted EBITDA up 43% compared with
the prior-year period to $27.7 million
- Net Income Available to Common
Shareholders increases to $0.11 per fully diluted share from a net
loss of $(0.06) per fully diluted share in the prior-year
period
- Adjusted Net Income per fully
diluted share increases 55% to $0.31 compared with the prior-year
period
- Free cash flow generation remains
strong at in excess of 50% of Adjusted EBITDA
- Offshore volume continues to improve
and is on track to reach goal of 50% at year end; volumes edited
post speech recognition increases to 74% of total volume
- Signs definitive agreement to
acquire M*Modal for $77.2 million in cash and 4.1 million shares of
common stock
- Receives notice of early termination
of HSR waiting period on M*Modal acquisition
The highlights above, as well as the discussion below, contain
certain non-GAAP financial measures that, together with applicable
GAAP financial measures, we utilize to evaluate the results of our
performance. Refer to the section of this release entitled
“Non-GAAP Financial Measures” for further discussion, as well as
the tables attached to this release that reconcile these non-GAAP
financial measures to applicable GAAP financial measures.
MedQuist Holdings Inc. (NASDAQ: MEDH), a leading provider of
integrated clinical documentation solutions for the U.S. healthcare
industry, announced its financial results for the three and six
months ended June 30, 2011.
M*Modal Acquisition
The Company also announced that it has received notice of early
termination of the mandatory, pre-merger waiting period under the
Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in
connection with the previously announced acquisition of M*Modal.
The transaction is expected to close by the end of August 2011 and
is subject to customary closing conditions.
Vern Davenport, Chairman and Chief Executive Officer of MedQuist
Holdings, said, “We are excited about clearing this regulatory
hurdle and will be working to integrate the businesses as quickly
as possible. Existing and prospective customers have responded well
to this transaction and have embraced our vision of helping them
accelerate adoption of EHRs to achieve meaningful use and better
position them in the move to a value-based healthcare delivery
system.”
Operating Results
Net revenues were $108.4 million for the second quarter of 2011
compared with $108.5 million for the second quarter of 2010.
The Spheris acquisition in April 2010 contributed $6.9 million of
additional revenues during the three months ended June 30, 2011,
arising from a full period consolidation, offset by a decrease in
price due to higher utilization of speech recognition and offshore
volumes by customers. In addition, net volumes were affected by
longer implementation cycles associated with EHR strategies of
large delivery systems, for which the Company has a large
concentration of customers, and some softness in the acute care
market, offset by the Company’s 98% customer retention rate.
As we stated last quarter, demand for our offshore resources
remains strong with related inventory growing. We continue to build
capacity in India and steadily migrate customer implementations to
reach our goal of 50% of volumes by year-end, which had an adverse
impact in the second quarter but is expected to result in higher
per unit contribution as we reach that offshore volume goal.
Adjusted EBITDA for the second quarter of 2011 was $27.7
million, or 25.6% of net revenues, compared with $19.4 million, or
17.9% of net revenues, for the second quarter of 2010. The
year-over-year increase in Adjusted EBITDA and margin is the result
of higher utilization of offshore resources and higher percentage
of volume edited post speech recognition, as well as synergies
realized from adding volumes from the Spheris acquisition to our
scalable platform.
Adjusted net income for the second quarter of 2011 was $16.6
million, or $0.31 per fully diluted share, compared with $10.4
million, or $0.20 per fully diluted share, in the second quarter of
2010. Net income available to common shareholders for the second
quarter of 2011 was $5.5 million, or $0.11 per fully diluted share,
compared with a net loss of $2.2 million, or $(0.06) per fully
diluted share, reported in the second quarter of 2010.
During the three months ended June 30, 2011, we recorded
restructuring charges of $2.0 million including approximately
$1.1 million from a reduction in workforce associated with the
integration of MedQuist Inc. and MedQuist Holdings. The benefits
from these restructuring efforts are expected to be fully realized
beginning in 2012.
Second Quarter
Operating Metrics
Q2 2011
Q1 2011
Q2 2010 Total clinical documentation volume: 855 million lines 866
million lines 800 million lines Transcription volumes processed
offshore:
42%
41%
39% Transcription volumes edited post speech recognition:
74%
72%
62%
Mr. Davenport noted, “During the quarter, we increased
utilization of speech recognition within our existing book of
business and steadily migrated volume to offshore resources. The
mid-July announcement of our agreement to acquire M*Modal also
highlighted the success in sourcing attractive acquisitions that
can leverage our core transcription business, enable new avenues
for growth and provide further technology differentiation within
the market.”
Net revenues were $219.7 million for the six months ended June
30, 2011, compared with $193.6 million for the six months
ended June 30, 2010. The Spheris acquisition in April 2010
contributed approximately $37.8 million in incremental revenue for
the six months ended June 30, 2011, arising from a full period
consolidation, offset by a decrease in price due to higher speech
recognition and offshore volumes and the longer implementation
cycles and broader acute care softness experienced in the second
quarter of 2011.
Adjusted EBITDA for the six months ended June 30, 2011, was
$55.2 million, or 25.1% of net revenues, compared with $33.4
million, or 17.2% of net revenues, for the six months ended June
30, 2010. The year-over-year increase in Adjusted EBITDA and margin
is the result of higher utilization of offshore resources and
higher percentage of volume edited post speech recognition, as well
as synergies realized from adding volumes from the Spheris
acquisition to our scalable platform.
Adjusted net income for the six months ended June 30, 2011, was
$34.0 million, or $0.66 per fully diluted share, compared with
$18.9 million, or $0.37 per fully diluted share, in the six months
ended June 30, 2010. Net income available to common shareholders
for the six months ended June 30, 2011, was $7.8 million, or $0.17
per fully diluted share, compared with a net loss available to
common shareholders of $0.8 million, or $(0.02) per fully diluted
share, for the six months ended June 30, 2010.
During the six months ended June 30, 2011, we recorded
restructuring charges of $7.4 million, including approximately
$5.4 million from a reduction in workforce (including $0.8
million for acceleration of stock option plans) and a charge of
$1.9 million related to office closures.
Six Months Operating Metrics
Six Months EndedJune 30, 2011
Six Months Ended
June 30, 2010
Total clinical documentation volume: 1.7 billion lines 1.4 billion
lines Transcription volumes processed offshore: 42% 40%
Transcription volumes edited post speech recognition: 73% 60%
Liquidity and Capital
Structure
As of June 30, 2011, the Company had $60.8 million in cash and
$269.8 million in debt. Free cash flow for the second quarter of
2011 increased to $16.7 million compared with $11.2 million in the
prior-year period. Capital expenditures for the second quarter of
2011 were $4.2 million compared with $3.7 million in the prior-year
period.
The Company’s high level of cash generated as compared to its
Adjusted EBITDA reflects its continued ability to utilize available
tax attributes to absorb current period taxes. At December 31,
2010, the Company had federal net operating loss carry forward
amounts of approximately $102 million with approximately 80%
available through 2014 to help off-set future period taxable income
amounts, subject to annual limitations. Additionally, the Company
had approximately $194 million of capitalized tax intangibles, of
which approximately 60% are expected to be amortized for tax
purposes, on a declining basis, over the next five years. These tax
attributes are anticipated to result in low cash tax amounts paid
in the near term.
In accordance with the terms of a Stipulation of Settlement
entered into in connection with the settlement of certain MedQuist
Inc. shareholder litigation during the second quarter of 2011, the
remaining issued and outstanding shares of MedQuist Inc. not
already owned by the Company are expected to be exchanged on the
same terms as the public exchange initiated on February 3, 2011
(the “Initial Exchange Offer”), through a short-form merger that is
expected to be completed by the end of the fourth quarter of 2011.
Prior to the short-form merger, the Company expects to conduct a
second public exchange offer on the same terms as the Initial
Exchange Offer.
Performance Goals for 2011 (Excluding
M*Modal)
The Company continues to be within its previously issued ranges
for Adjusted EBITDA and Adjusted Net Income, which exclude any
effect from acquisitions. Based on current volume trends, the
Company now expects fiscal 2011 total clinical documentation volume
will increase 6% to 13% compared with the 3.1 billion lines
achieved in 2010.
Total clinical documentation
volume: 3.3 billion to 3.5 billion lines Adjusted EBITDA: $113
million to $116 million Adjusted Net Income: $1.26 to $1.33 per
fully diluted share
Commenting on the 2011 outlook, Mr. Davenport added, “From an
earnings perspective, we are right where we need to be halfway
through the year and will be adding another layer of growth to the
company when we complete the M*Modal acquisition and integration.
Although some larger customers’ requests to extend implementation
schedules and allow extra time for their EHR initiatives as well as
lower-than-anticipated bookings will affect our volumes for the
year, I’m encouraged by my early customer and prospect calls and
the response to our enhanced value proposition with the joining of
M*Modal. It’s clear that our customers want to capitalize on the
leverage we can provide through our scale and can see the value of
us coming together to drive EHR adoption, improve clinical
effectiveness and enable their financial success. Additionally, I
see opportunities for us to improve sales and implementation cycles
to further improve volume and revenue trends.”
Investor Conference Call and Web
Simulcast
MedQuist Holdings will host a conference call on August 16,
2011, at 8:00 a.m. CT to discuss its results of operations for the
second quarter of 2011. The number to call for the interactive
teleconference is (212) 231-2901. A replay of the conference
call will be available through Monday, August 23, 2011, by dialing
(402) 977-9140 and entering the confirmation number, 21533198.
A live broadcast of MedQuist Holdings quarterly conference call
will be available online at the Company's website,
www.medquist.com, under Investor Relations on August 16, 2011,
beginning at 8:00 a.m. CT. The online replay will follow
shortly after the call and continue for one year.
About MedQuist Holdings
MedQuist is a leading provider of medical transcription
services, and a leader in technology-enabled clinical documentation
workflow. MedQuist's enterprise solutions – including mobile voice
capture devices, speech recognition, Web-based workflow platforms,
and global network of medical editors – help healthcare facilities
improve patient care, increase physician satisfaction, and lower
operational costs. For more information, please visit
www.medquist.com.
Forward-Looking
Statements
Information provided and statements contained in this press
release that are not purely historical, such as statements
regarding our 2011 financial and operating performance and the
proposed acquisition of M*Modal, are forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements only speak as of the date of this press release and the
Company assumes no obligation to update the information included in
this press release. Statements made in this press release that are
forward-looking in nature may involve risks and uncertainties.
Accordingly, readers are cautioned that any such forward-looking
statements are not guarantees of future performance and are subject
to certain risks, uncertainties and assumptions that are difficult
to predict, including, without limitation, specific factors
discussed herein and in other releases and public filings made by
the Company (including filings by the Company with the Securities
and Exchange Commission). Although the Company believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Unless otherwise required by law, the
Company also disclaims any obligation to update its view of any
such risks or uncertainties or to announce publicly the result of
any revisions to the forward-looking statements made in this press
release.
This communication does not constitute an offer to sell or the
solicitation of an offer to buy any securities or a solicitation of
any vote or approval. The offer to exchange the Company’s shares
for MedQuist Inc. shares, if made, will only be made pursuant to a
Registration Statement on Form S-4, a letter of transmittal and
related offer documents to be filed by the Company with the SEC.
INVESTORS AND SECURITY HOLDERS OF MEDQUIST INC. ARE URGED TO READ
SUCH REGISTRATION STATEMENT ON FORM S-4 AND OTHER DOCUMENTS FILED
WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE
BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE
CONTEMPLATED EXCHANGE OFFER AND MERGER. UPON FILING WITH THE SEC,
THE REGISTRATION STATEMENT AND RELATED DOCUMENTS WILL BE AVAILABLE
FREE ON THE SEC’S WEBSITE (HTTP://WWW.SEC.GOV). Holders of MedQuist
Inc. shares will need to make their own decision whether to tender
shares in the contemplated exchange offer. Neither MedQuist Inc.
nor any other person is making any recommendation as to whether or
not holders of MedQuist Inc. shares should tender their shares for
exchange in the contemplated exchange offer.
MedQuist Holdings Inc. and Subsidiaries
Consolidated Statements of Operations (In thousands,
except per share amounts) Unaudited
Three Months Ended Six Months Ended
June 30, June 30, 2011 2010 2011
2010 Net revenues $ 108,439 $ 108,505 $ 219,675 $
193,592 Cost of revenues 65,151 70,335
130,637 124,950
Gross Profit
43,288 38,170 89,038
68,642
Operating costs and expenses:
Selling, general and administrative 13,991 15,619 30,267 30,099
Research and development 2,190 3,312 4,892 5,593 Depreciation and
amortization 8,879 8,481 17,297 14,620 Cost (benefit) of legal
proceedings, settlements and accommodations 581 1,109 (6,932 )
2,152
Acquisition and restructuring
4,391 6,027 11,269
7,011
Total operating costs and expenses
30,032 34,548 56,793
59,475 Operating income 13,256 3,622 32,245 9,167 Equity in
income of affiliated company - 32 - 546 Other income (expense) (3 )
1 7 78 Interest expense, net (6,961 ) (5,437 )
(13,998 ) (7,306 )
Income (loss) from continuing
operations before income taxes and noncontrolling interests
6,292 (1,782 ) 18,254 2,485 Income tax provision (benefit)
886 (362 ) 2,030 (382 )
Net
income (loss) from continuing operations $ 5,406 $
(1,420 ) $ 16,224 $ 2,867
Income from
discontinued operations, net of tax - 153
- 183
Net income (loss)
5,406 (1,267 ) 16,224 3,050 Less: Net income attributable to
noncontrolling interests (271 ) (268 ) (1,777
) (2,497 )
Net income (loss) attributable to MedQuist
Holdings Inc. $ 5,135 $ (1,535 ) $ 14,447 $ 553
Net income (loss) per common share from continuing
operations Basic $ 0.11 $ (0.06 ) $ 0.17 $ (0.03
) Diluted $ 0.11 $ (0.06 ) $ 0.17 $ (0.03 )
Net income per common share from discontinued operations
Basic $ - $ - - 0.01
Diluted $ - $ - - 0.01
Net income (loss) per common share attributable to
MedQuist Holdings Inc. Basic $ 0.11 $ (0.06 ) $ 0.17
$ (0.02 ) Diluted $ 0.11 $ (0.06 ) $ 0.17 $
(0.02 ) Weighted average shares outstanding: Basic 49,168
35,078 45,128 35,046
Diluted 50,559 35,078
46,410 35,046
Calculation of
net income (loss) available for common shareholders
Three Months Ended Six Months Ended June
30, June 30, 2011 2010 2011
2010 Net income (loss) attributable to MedQuist
Holdings $ 5,135 $ (1,535 ) $ 14,447 $ 553 Less: amount
attributable to former principal shareholders 400
(688 ) (6,619 ) (1,375 )
Net income (loss)
available for common shareholders 5,535
(2,223 ) 7,828
(822 ) MedQuist Holdings Inc. and
Subsidiaries Consolidated Balance Sheets (In
thousands, except par value) Unaudited June
30, December 31, 2011 2010 Assets
Current assets: Cash and cash equivalents $ 60,801 $ 66,779
Accounts receivable, net of allowance of $1,707 and $1,466,
respectively 74,025 82,038 Other current assets 24,900
23,706 Total current assets 159,726 172,523
Property and equipment, net 21,984 23,018 Goodwill 90,328
90,268 Other intangible assets, net 102,552 107,962 Deferred income
taxes 7,089 6,896 Other assets 17,400 14,212
Total assets $ 399,079 $ 414,879
Liabilities and Equity Current liabilities: Current portion
of long-term debt $ 12,025 $ 27,817 Accounts payable 14,921 11,358
Accrued expenses 29,663 36,917 Accrued compensation 9,731 16,911
Related party payable 4,000 - Deferred revenue 8,553
10,570 Total current liabilities 78,893 103,573
Long-term debt 257,807 266,677 Deferred income taxes 5,666 4,221
Related party payable, non-current - 3,537 Other non-current
liabilities 2,658 2,360 Total
liabilities 345,024 380,368 Commitments
and contingencies Total equity: Preferred stock - $0.10 par value;
authorized 25,000 shares; none issued or outstanding - - Common
stock - $0.10 par value; authorized 300,000 shares; 49,168 and
35,158 shares issued and outstanding, respectively 4,917 3,516
Additional paid-in-capital 142,336 148,265 Accumulated deficit
(92,732 ) (107,179 ) Accumulated other comprehensive loss
(139 ) (663 ) Total MedQuist Holdings Inc. stockholders'
equity 54,382 43,939 Noncontrolling interests (327 )
(9,428 ) Total equity 54,055 34,511 Total liabilities and
equity $ 399,079 $ 414,879
MedQuist
Holdings Inc. and Subsidiaries Consolidated Statements of
Cash Flows (In thousands) Unaudited
Six Months Ended June 30, 2011 2010
Operating activities: Net income $ 16,224 3,050 Adjustments
to reconcile net income to cash provided by operating activities:
Depreciation and amortization 17,297 15,068 Equity in income of
affiliated company - (546 ) Deferred income taxes 1,472 205 Share
based compensation 1,230 322 Provision for doubtful accounts 220
1,085 Non-cash interest expense 1,572 - Other (608 ) (555 ) Changes
in operating assets and liabilities: Accounts receivable 6,206
1,741 Other current assets (4,658 ) (4,064 ) Other non-current
assets (5,024 ) 918 Accounts payable (665 ) (5,379 ) Accrued
expenses (1,549 ) (382 ) Accrued compensation (7,141 ) (151 )
Deferred revenue (2,017 ) (994 ) Other non-current liabilities
396 3,438 Net cash provided by
operating activities 22,955 13,756
Investing activities: Purchase of property and
equipment (5,368 ) (3,129 ) Purchases of capitalized intangible
assets (5,564 ) (3,584 ) Payments for acquisitions and interests in
affiliates, net of cash acquired - (98,310 )
Net cash used in investing activities (10,932 )
(105,023 )
Financing activities: Proceeds from debt
2,113 107,216 Repayment of debt (27,092 ) (16,519 ) Debt issuance
costs - (6,070 ) Net proceeds from issuance of common stock
6,781 - Net cash (used in) provided by
financing activities (18,198 ) 84,627
Effect of exchange rate changes 197 (536 ) Net decrease in cash and
cash equivalents (5,978 ) (7,176 ) Cash and cash equivalents -
beginning of period 66,779 29,633
Cash and cash equivalents - end of period $ 60,801 $
22,457
MedQuist Holdings Inc.
and Subsidiaries Reconciliation of Net Income (Loss) to
Adjusted EBITDA (In thousands) Unaudited
Three Months Ended Six Months Ended June 30,
June 30, 2011 2010 2011
2010 Net income (loss) attributable to MedQuist
Holdings Inc. $ 5,135 $ (1,535 ) $ 14,447 $ 553 Net income
attributable to noncontrolling interest 271 268 1,777 2,497
Discontinued operations - (153 ) - (183 ) Income tax provision
(benefit) 886 (362 ) 2,030 (382 ) Interest expense, net 6,961 5,437
13,998 7,306 Depreciation and amortization 8,879 8,481 17,297
14,620 Acquisition and restructuring charges 4,391 6,027 11,269
7,011
Cost (benefit) of legal proceedings,
settlements and accommodations
581 1,109 (6,932 ) 2,152 Share-based compensation and other
non-cash awards 611 181 1,320 322 Equity in income of affiliated
company - (32 ) -
(546 ) Adjusted EBITDA $ 27,715 $ 19,421
$ 55,206 $ 33,350 Adjusted EBITDA as a
percentage of net revenue 25.6 % 17.9 %
25.1 % 17.2 %
MedQuist
Holdings Inc. and Subsidiaries Free Cash Flow (In
thousands) Unaudited Three Months Ended
Six Months Ended June 30, June 30, 2011
2010 2011 2010 Adjusted
EBITDA $ 27,715 $ 19,421 $ 55,206 $ 33,350 Less:
Consolidated interest expense (6,961 ) (5,437 ) (13,998 ) (7,306 )
Add: Non-cash interest 714 - 1,572 - Less: Capital expenditures
(4,244 ) (3,676 ) (10,932 ) (6,713 ) Less: Tax provision (886 ) 362
(2,030 ) 382 Add: Deferred tax provision 381
564 1,472 205 Free
Cash Flow $ 16,719 $ 11,234 $ 31,290
$ 19,918 Adjusted Net Income: Adjusted EBITDA
$ 27,715 $ 19,421 $ 55,206 $ 33,350 Less: Amortization (excluding
acquired intangibles) 4,362 4,547 8,265 7,719
Cash interest (total expenses less non-cash) 6,247 5,437 12,426
7,306
Current tax provision (benefit) 505
(926 ) 558 (587 ) Adjusted Net Income $
16,601 $ 10,363 $ 33,957 $
18,912
Adjusted Net Income Per Share:
Basic
$
0.32
$
0.20
$
0.68
$
0.37
Diluted
$
0.31
$
0.20
$
0.66
$
0.37
MedQuist Holdings Inc. and
Subsidiaries Share Calculation (In thousands)
Unaudited Three Months Ended Six Months
Ended June 30, June 30, 2011 2010
2011 2010 MedQuist Holdings Shares Basic
outstanding 49,168 35,078 45,128 35,046 Effect of diluted Options
1,391 - 1,282 - Diluted shares 50,559 35,078 46,410 35,046
Proforma impact of fully dilutive stock (1) Basic 1,929 15,775
5,085 15,775 Diluted 2,176 16,005 5,332 16,005 Proforma
Shares Proforma basic 51,097 50,853 50,213 50,821 Proforma diluted
52,735 51,083 51,742 51,051 (1) Fully dilutive shares
includes common stock equivalents which consists of stock options,
restricted stock issuable to certain key employees, shares issued
to former principal stockholders, shares issued in our Initial
Public Offering, Private Exchange and Initial Exchange Offer and
shares issuable to remaining noncontrolling shareholders of
MedQuist Inc.
Total Clinical Documentation Volume
Management believes that total clinical documentation volume is
an important measure of the Company’s operating results. Total
clinical documentation volume is defined as total lines processed
on our clinical documentation platforms and/or transcribed or
edited by our personnel.
Non-GAAP Financial
Measures
In addition to the United States generally accepted
accounting principles, or GAAP, results provided throughout this
document, MedQuist Holdings Inc. has provided certain
non-GAAP financial measures to help evaluate the results of our
performance. The Company believes that these non-GAAP financial
measures, when presented in conjunction with comparable GAAP
financial measures, are useful to both management and investors in
analyzing the Company’s ongoing business and operating performance.
The Company believes that providing the non-GAAP information to
investors, in addition to the GAAP presentation, allows investors
to view the Company’s financial results in the way that management
views financial results. The tables attached to this press release
include a reconciliation of these historical non-GAAP financial
measures to the most directly comparable GAAP financial
measures.
We also present Adjusted EBITDA and Adjusted Net Income on a
forward-looking basis as part of our Performance Goals for 2011. We
are unable to present a quantitative reconciliation of these
forward-looking non-GAAP financial measures to the most directly
comparable forward-looking GAAP financial measures because
management cannot predict, with sufficient reliability,
contingencies relating to potential changes in tax valuation
allowances, potential changes to customer accommodation accruals,
potential restructuring impacts, contingencies related to past and
future acquisitions, and changes in fair values of our derivative
instruments, all of which are difficult to estimate primarily due
to dependencies on future events.
Adjusted EBITDA
Adjusted EBITDA is a metric used by management to measure
operating performance. Adjusted EBITDA is defined as net income
(loss) attributable to MedQuist Holdings Inc., as applicable, plus
net income attributable to noncontrolling interests, income taxes,
interest expense, net, depreciation and amortization, cost
(benefit) of legal proceedings, settlements, and accommodations,
acquisition and restructuring charges, the effect of the sale of
our Patient Financial Services business (discontinued operations),
equity in income of affiliated company and share based compensation
and other non cash awards.
We present Adjusted EBITDA as a supplemental performance measure
because we believe it facilitates operating performance comparisons
from period to period and company to company by backing out the
following:
- potential differences caused by
variations in capital structures (affecting interest expense, net),
tax positions (such as the impact on periods or companies for
changes in effective tax rates), the age and book depreciation of
fixed assets (affecting depreciation expense);
- the impact of non-cash charges;
and
- the impact of acquisition and
integration related charges, restructuring charges, and certain
unusual or nonrecurring items.
Because Adjusted EBITDA facilitates internal comparisons of
operating performance on a more consistent basis, we also use
Adjusted EBITDA in measuring our performance relative to that of
our competitors. Adjusted EBITDA is not a measurement of our
financial performance under GAAP and should not be considered as an
alternative to net income, operating income or any other
performance measures derived in accordance with GAAP or as an
alternative to cash flow from operating activities as measures of
our profitability or liquidity. We understand that although
Adjusted EBITDA is frequently used by securities analysts, lenders
and others in their evaluation of companies, Adjusted EBITDA has
limitations as an analytical tool, and you should not consider it
in isolation, or as a substitute for analysis of our results as
reported under GAAP. Some of these limitations are:
- Adjusted EBITDA does not reflect our
cash expenditures or future requirements for capital expenditures
or contractual commitments;
- Adjusted EBITDA does not reflect
changes in, or cash requirements for, our working capital
needs;
- Although depreciation is a non-cash
charge, the assets being depreciated will often have to be replaced
in the future, and Adjusted EBITDA does not reflect any cash
requirements for such replacements; and
- Other companies in our industry may
calculate Adjusted EBITDA differently than we do, limiting its
usefulness as a comparative measure.
Free Cash Flow
Free Cash Flow, a non-GAAP financial measure, is defined by the
Company as Adjusted EBITDA less consolidated interest expense (net
of non-cash interest), less capital expenditures (including
capitalized software development costs), and less current tax
provision. Management believes that utilization of Free Cash Flow
is an important non-GAAP measure of the Company’s ability to
convert operating results into cash.
Adjusted Net Income
Adjusted Net Income, a non-GAAP financial measure, is defined by
the Company as Adjusted EBITDA less amortization expense for
capitalized intangible assets (excluding acquired intangibles),
less interest expense (net of non-cash interest), and less current
tax provision. We measure Adjusted Net Income based on Proforma
Shares Outstanding (see below). Management believes that
utilization of Adjusted Net Income is an important non-GAAP
financial measure of our normalized operating results.
Proforma Shares Outstanding
For purposes of evaluating our results on per-share metrics,
many of our computations utilize proforma share computations. Our
measure of proforma shares includes our Basic and Diluted share
computations utilized for GAAP purposes, plus our estimate of the
impacts of common stock equivalents which consists of stock
options, restrictive stock issuable to certain key employees,
shares issued to former principal stockholders, shares issued in
our Initial Public Offering, Private Exchange and Initial Exchange
Offer and shares issuable to remaining noncontrolling shareholders
of MedQuist Inc.
Medx (CE) (USOTC:MEDH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Medx (CE) (USOTC:MEDH)
Historical Stock Chart
From Jul 2023 to Jul 2024